Sun Pharma Q3 results: Consolidated net profit rises 5 percent YoY

Published On 2023-01-31 07:00 GMT   |   Update On 2023-01-31 12:13 GMT

New Delhi: Sun Pharma on Tuesday reported a consolidated net profit of Rs 2,166 crore for the third quarter ended December 31, 2022.The Mumbai-based company had posted a net profit of Rs 2,059 crore for October-December period of the previous fiscal year.Total revenue from operations stood at Rs 11,241 crore in the period under review. It was Rs 9,863 crore in the year-ago quarter,...

Login or Register to read the full article

New Delhi: Sun Pharma on Tuesday reported a consolidated net profit of Rs 2,166 crore for the third quarter ended December 31, 2022.

The Mumbai-based company had posted a net profit of Rs 2,059 crore for October-December period of the previous fiscal year.

Total revenue from operations stood at Rs 11,241 crore in the period under review. It was Rs 9,863 crore in the year-ago quarter, Sun Pharmaceutical Industries said in a regulatory filing.

On February 28, 2022, the company’s subsidiary Taro Pharmaceutical Industries had acquired all of the outstanding capital stock of Galderma Holdings Inc; Proactiv YK ; The Proactiv Company Corporation ; and its other assets, the drug major said.

Accordingly, results for the quarter and nine months ended December 31, 2022 are not comparable to the year-ago periods’, it noted.

The company’s board, which met on Tuesday, also approved an interim dividend of Rs 7.50 per share of Re 1 for 2022-23.

Read also: Sun Pharma Gets CDSCO panel nod for active post marketing surveillance of Tofacitinib ER Tablets

Sun Pharma is an Indian multinational pharmaceutical company headquartered in Mumbai, Maharashtra. The company manufactures and markets a large basket of pharmaceutical formulations covering a broad spectrum of chronic and acute therapies. It includes generics, branded generics, specialty, complex or difficult-to-make technology-intensive products, over-the-counter (OTC), antiretrovirals (ARVs), Active Pharmaceutical Ingredients (APIs), and Intermediates.

Read also: Laurus Labs reports 32.1 percent rise in Q3 profit

Tags:    
Article Source : with inputs

Disclaimer: This site is primarily intended for healthcare professionals. Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement/treatment or prescription. Use of this site is subject to our terms of use, privacy policy, advertisement policy. © 2024 Minerva Medical Treatment Pvt Ltd

Our comments section is governed by our Comments Policy . By posting comments at Medical Dialogues you automatically agree with our Comments Policy , Terms And Conditions and Privacy Policy .

Similar News